Overview

Neoadjuvant Endocrine Therapy in Breast Cancer

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
0
Participant gender:
Female
Summary
The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Guangdong General Hospital
Guangdong Provincial People's Hospital
Treatments:
Letrozole
Criteria
Inclusion Criteria:

1. Females ≥18 years

2. ER-positive (≥50%), PgR-positive (≥50% ), HER2-negative, and previously untreated,
non-metastatic primary invasive BC.

3. The tumour size had to be >1 cm.

Exclusion Criteria:

1. male patients;

2. patients with inflammatory breast cancer or distant metastasis;

3. patients who were previously treatment treated with chemotherapy, radiation therapy or
prior treatment with AIs or antiestrogens for breast cancer;

4. patients with a second concomitant neoplasm;

5. patients who could not meet the eligibility criteria.